This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

• Initial Treatment of HCV Infection
• Retreatment of Persons in Whom Prior Therapy has Failed
• Unique Patient Populations: Patients with Renal Impairment
   

Other updates reflecting recent data are provided in:

• Unique Patient Populations: Patients with Decompensated Cirrhosis
• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
• HCV Testing and Linkage to Care
   

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

• Monitoring Patients who are Starting Hepatitis C Treatment, are on Treatment, or have Completed Therapy section.
   

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

• Unique Patient Populations: Patients with HIV/HCV Coinfection
• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
   

Updated references have been provided throughout the Guidance.